

July 30, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Entering into a binding agreement for transfer of shares of CuraTeQ Biologics s.r.o., by Helix Healthcare B.V., to Curateq Biologics B.V., wholly owned subsidiaries of the Company.

This is to inform you that a binding agreement has been entered into on July 29, 2025, for transfer of the entire shares of CuraTeQ Biologics s.r.o., held by Helix Healthcare B.V., to Curateq Biologics B.V. All these companies are wholly owned subsidiaries / step down subsidiaries of the Company. After completion of the above share transfer, Curateq Biologics s.r.o., Czech Republic, would become a wholly owned subsidiary of Curateq Biologics B.V., The Netherlands.

The details required in terms of Regulation 30 of the SEBI Listing Regulations are provided in **Annexure**.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure

a	Name of the target entity, details in brief such as size, turnover etc.;	<p>Helix Healthcare B.V, The Netherlands, a wholly owned subsidiary of the Company (“Helix”), is holding 100% share capital of Curateq Biologics s.r.o., Czech Republic, a wholly owned step-down subsidiary of the Company (“CuraTeQ SRO”). CuraTeQ Biologics B.V, The Netherlands, (“CuraTeQ BV”) was incorporated on May 28, 2025 as a wholly owned subsidiary of CuraTeQ Biologics Private Limited, India., a wholly owned subsidiary of the Company.</p> <p>A binding Share Purchase Agreement has been entered into on July 29, 2025, whereby Helix would transfer its 100% stake in CuraTeQ SRO to CuraTeQ BV.</p> <p>The following are the details of turnover and net-worth of these companies for the year ended March 31, 2025:</p> <table border="1"> <thead> <tr> <th>Name of company</th><th>Turnover (INR Millions)</th><th>Net-worth (INR Millions)</th></tr> </thead> <tbody> <tr> <td>Helix</td><td>Nil</td><td>29,317.4</td></tr> <tr> <td>CuraTeQ BV*</td><td>NA</td><td>NA</td></tr> <tr> <td>CuraTeQ SRO</td><td>Nil</td><td>207.4</td></tr> </tbody> </table> <p>* CuraTeQ BV was incorporated on May 28, 2025.</p>	Name of company	Turnover (INR Millions)	Net-worth (INR Millions)	Helix	Nil	29,317.4	CuraTeQ BV*	NA	NA	CuraTeQ SRO	Nil	207.4
Name of company	Turnover (INR Millions)	Net-worth (INR Millions)												
Helix	Nil	29,317.4												
CuraTeQ BV*	NA	NA												
CuraTeQ SRO	Nil	207.4												
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>Helix is a wholly owned subsidiary of the Company and CuraTeQ BV and CuraTeQ SRO are wholly owned step-down subsidiaries of the Company and all of them are related parties as per Regulation 2 (zb) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</p> <p>The transaction being undertaken among the wholly owned subsidiaries of the Company, hence there is no impact on a consolidated basis.</p> <p>As per the provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions among wholly owned subsidiaries of the Company.</p>												
c	Industry to which the entity being acquired belongs;	Manufacturing and marketing of pharmaceutical products.												

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihaar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To make Curateq Biologics s.r.o, a wholly owned subsidiary of CuraTeQ Biologics B.V. as part of verticalization of biologics /biosimilars business of CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company.								
e	Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental or regulatory approvals required.								
f	Indicative time period for completion of the acquisition;	On or before August 31, 2025								
g	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration								
h	Cost of acquisition and/or the price at which the shares are acquired;	EUR 3,000,000 (INR 303 million)								
i	Percentage of shareholding / control acquired and / or number of shares acquired;	100%								
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<div>Curateq Biologics s.r.o is a wholly owned step-down subsidiary of the Company incorporated on July 27, 2021 in Czech Republic for marketing of pharmaceutical products.</div> <div>Turnover of Curateq Biologics s.r.o for the last 3 years</div> <table><tr><th>Year</th><th>Turnover (Rs. in million)</th></tr><tr><td>2024-25</td><td>Nil</td></tr><tr><td>2023-24</td><td>Nil</td></tr><tr><td>2022-23</td><td>Nil</td></tr></table>	Year	Turnover (Rs. in million)	2024-25	Nil	2023-24	Nil	2022-23	Nil
Year	Turnover (Rs. in million)									
2024-25	Nil									
2023-24	Nil									
2022-23	Nil									

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com